UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of the registrant as specified in its charter) Delaware 87-1082097 ...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2021 Earnings Conference Call March 10, 2022 8:30 AM ET Company Participants Allison Wey - SVP, IR and Corporate Communications Paul Edick - Chairman and CEO Steve Pieper - CFO Conference Call Participants Roanna Ruiz - SVB Leerink Vamil Divan - Mizuho Securities David Amsellem - Piper Sandler Operator Hello everyone. And welcome to the Xeris Biopharma Fourth Quarter 2021 Financial Results Conference Call and Webcast. My name is Seth and I will be the operator ...

Xeris Biopharma (Nasdaq: XERS) A biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology February 2022 Copyright ©2017-2021 Xeris Pharmaceuticals, Inc. All rights reserved. Forward-looking statements 2 Any statements in this presentation about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc. including statements regarding the market and therapeutic potential of its products and product cand ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of the registrant as specified in its charter) Delaware 87 ...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2021 Earnings Conference Call November 10, 2021 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations and Corporate Communications Paul Edick - Chairman and Chief Executive Officer Steve Pieper - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Oren Livnat - H.C. Wainwright David Steinberg - Jefferies Alexandre Bouilloux - Mizuho Securities Kelley Prince - Close Concerns Operator Welcome to ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | | | | Forward-looking statements 2 This document contains forward‐looking statements relating to the Company's strategy, objectives, business development plans, financial position, clinical development, regulatory plans and revenue guidance. All statements other than statements of historical facts included in this document, including, without limitation, statements regarding the Company's future financial position, strategy, anticipated ...

Strongbridge Biopharma plc (SBBP) Q1 2021 Earnings Conference Call May 12, 2021 8:30 AM ET Company Participants Lindsay Rocco - Elixir Health, Public Relations John Johnson - CEO Fredric Cohen - CMO Richard Kollender - President and CFO Scott Wilhoit - CCO Officer Conference Call Participants Roger Song - Jefferies Annabel Samimy - Stifel Jonathan Wolleben - JMP Securities Robin Garner - Craig-Hallum Operator Good morning ladies and gentlemen and welcome to the Strongbridge Biopharma Plc Corporate Update an ...

| --- | --- | |----------------------|-------| | | | | | | | Unlocking the | | | potential of today's | | | | | | medicines for | | | profound impact | | March 2021 Xeris Pharmaceuticals, Inc. ©2017-2020 All Rights Reserved Forward-looking Statements 2 This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the rate and degree of market acceptance and clinical utility of Gvoke®, the market and the the ...

Financial Data and Key Metrics Changes - For the full year 2020, net revenues from sales of KEVEYIS increased by $9 million or 41.5% from $21.7 million in 2019 to $30.7 million in 2020 [21] - Gross margins improved to 93% for 2020 compared to 82% in 2019 [21] - Selling, general and administrative expenses decreased to $40.9 million in 2020 from $49.1 million in 2019 [22] - Research and development expenses decreased to $25.8 million in 2020 from $30.9 million in 2019 [23] - The company ended 2020 with approximately $87.5 million in cash, expecting to have more than one year's worth of cash at the time of potential RECORLEV FDA approval [25][26] Business Line Data and Key Metrics Changes - KEVEYIS revenues for Q4 2020 were $8.2 million, exceeding the projected guidance range of $28 million to $29 million for the full year [14] - The company is actively preparing for the launch of RECORLEV, having submitted its New Drug Application to the FDA [9][12] Market Data and Key Metrics Changes - The company is focused on the Cushing's syndrome market, which has an estimated 8,000 patients in the US who are treated with prescription therapy [10] - The competitive landscape includes ISTURISA, which has been benchmarked against RECORLEV [32] Company Strategy and Development Direction - The company aims to leverage its rare disease commercialization expertise to bring RECORLEV to market [13] - There is a focus on maintaining and growing the active patient base for KEVEYIS while preparing for RECORLEV's launch [15][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of KEVEYIS despite the challenges posed by the COVID-19 pandemic [8] - The company anticipates that increased vaccination rates will improve patient access to healthcare providers, potentially leading to more diagnoses and treatments [16][82] - Management remains optimistic about the potential approval of RECORLEV and its market positioning [12][74] Other Important Information - The interim safety and efficacy results from the Phase 3 LOGICS study will be presented at the Endocrine Society's ENDO 2021 Annual Meeting [12] - The company is actively working on its go-to-market strategy for RECORLEV, including market access activities and healthcare provider research [18][19] Q&A Session Summary Question: What are the expectations for the Cushing's syndrome landscape and how does RECORLEV compare to ISTURISA? - Management believes RECORLEV has a competitive profile and sees opportunities in the underserved female population [33][34] Question: Can you provide updates on KEVEYIS performance during the pandemic? - Management attributes KEVEYIS's strong performance to proactive engagement with healthcare providers and patients [52][53] Question: What are the plans for Veldoreotide? - Management is still evaluating options for Veldoreotide and will provide updates in the future [41][42] Question: What can be expected from the ENDO presentation? - The presentation will provide detailed efficacy and safety analyses from the LOGICS study [50] Question: How many patients are currently being treated with KEVEYIS? - Management has not disclosed the exact number of patients but estimates there are 4,000 to 5,000 diagnosed PPP patients in the market [94][95] Question: What additional launch preparedness activities are needed for RECORLEV? - Key activities include market access, advocacy, and optimizing sales force structure [96][100]

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | | | | Forward-looking statements 2 This document contains forward‐looking statements relating to the Company's strategy, objectives, business development plans, financial position, clinical development, regulatory plans and revenue guidance. All statements other than statements of historical facts included in this document, including, without limitation, statements regarding the Company's future financial position, strategy, anticipated ...